The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls.

MLA

Schulz, Eduard, et al. “The TP53 Pro72Arg SNP in de Novo Acute Myeloid Leukaemia - Results of Two Cohort Studies Involving 215 Patients and 3759 Controls.” British Journal of Haematology, vol. 181, no. 1, Apr. 2018, pp. 148–51. EBSCOhost, https://doi.org/10.1111/bjh.14527.

APA

Schulz, E., Lind, K., Renner, W., Petersen, B.-S., Quehenberger, F., Dill, C., Hofer, S., Lal, R., Hoefler, G., Schlenke, P., Ehninger, G., Schetelig, J., Middeke, J. M., Stölzel, F., & Sill, H. (2018). The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls. British Journal of Haematology, 181(1), 148–151. https://doi.org/10.1111/bjh.14527

Chicago

Schulz, Eduard, Karin Lind, Wilfried Renner, Britt-Sabina Petersen, Franz Quehenberger, Claudia Dill, Sybille Hofer, et al. 2018. “The TP53 Pro72Arg SNP in de Novo Acute Myeloid Leukaemia - Results of Two Cohort Studies Involving 215 Patients and 3759 Controls.” British Journal of Haematology 181 (1): 148–51. doi:10.1111/bjh.14527.